Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 4 de 4
Filtrar
1.
Microbiol Spectr ; 12(5): e0407823, 2024 May 02.
Artigo em Inglês | MEDLINE | ID: mdl-38534121

RESUMO

Parasiticide fungi are considered an accurate, sustainable, and safe solution for the biocontrol of animal gastrointestinal (GI) parasites. This research provides an initial characterization of the virulence of the native parasiticide fungus Mucor circinelloides (FMV-FR1) and an assessment of its impact on birds' gut microbes. The genome of this fungus was sequenced to identify the genes coding for virulence factors. Also, this fungus was checked for the phenotypic expression of proteinase, lecithinase, DNase, gelatinase, hemolysin, and biofilm production. Finally, an in vivo trial was developed based on feeding M. circinelloides spores to laying hens and peacocks three times a week. Bird feces were collected for 3 months, with total genomic DNA being extracted and subjected to long-read 16S and 25S-28S sequencing. Genes coding for an iron permease (FTR1), iron receptors (FOB1 and FOB2), ADP-ribosylation factors (ARFs) (ARF2 and ARF6), and a GTPase (CDC42) were identified in this M. circinelloides genome. Also, this fungus was positive only for lecithinase activity. The field trial revealed a fecal microbiome dominated by Firmicutes and Proteobacteria in laying hens, and Firmicutes and Bacteroidetes in peacocks, whereas the fecal mycobiome of both bird species was mainly composed of Ascomycetes and Basidiomycetes fungi. Bacterial and fungal alpha-diversities did not differ between sampling time points after M. circinelloides administrations (P = 0.62 and P = 0.15, respectively). Although findings from this research suggest the lack of virulence of this M. circinelloides parasiticide isolate, more complementary in vitro and in vivo research is needed to conclude about the safety of its administration to birds, aiming at controlling their GI parasites.IMPORTANCEA previous study revealed that the native Mucor circinelloides isolate (FMV-FR1) can develop parasiticide activity toward coccidia oocysts, one of the most pathogenic GI parasites in birds. However, ensuring its safety for birds is of utmost importance, namely by studying its virulence profile and potential effect on commensal gut microbes. This initial study revealed that although this M. circinelloides isolate had genes coding for four types of virulence factors-iron permease, iron receptors, ADP-ribosylation factors, and GTPase-and only expressed phenotypically the enzyme lecithinase, the administration of its spores to laying hens and peacocks did not interfere with the abundances and diversities of their gut commensal bacteria and fungi. Although overall results suggest the lack of virulence of this M. circinelloides isolate, more complementary research is needed to conclude about the safety of its administration to birds in the scope of parasite biocontrol programs.


Assuntos
Galinhas , Microbioma Gastrointestinal , Mucor , Fatores de Virulência , Mucor/genética , Mucor/patogenicidade , Animais , Galinhas/microbiologia , Virulência , Fatores de Virulência/genética , Fatores de Virulência/metabolismo , Fezes/microbiologia , Feminino
2.
Med Mycol ; 57(3): 351-362, 2019 Apr 01.
Artigo em Inglês | MEDLINE | ID: mdl-29924357

RESUMO

Mucorales can cause cutaneous to deep-seated infections, mainly in the immunocompromised host, resulting in high mortality rates due to late and inefficient treatment. In this study, Galleria mellonella larvae were evaluated as a heterologous invertebrate host to study pathogenicity of clinically relevant mucormycetes (Rhizopus spp., Rhizomucor spp., Lichtheimia spp., Mucor spp.). All tested species were able to infect G. mellonella larvae. Virulence potential was species-specific and correlated to clinical relevance. Survival of infected larvae was dependent on (a) the species (growth speed and spore size), (b) the infection dose, (c) the incubation temperature, (d) oxidative stress tolerance, and (e) iron availability in the growth medium. Moreover, we exploited the G. mellonella system to determine antifungal efficacy of liposomal amphotericin B, posaconazole, isavuconazole, and nystatin-intralipid. Outcome of in vivo treatment was strongly dependent upon the drug applied and the species tested. Nystatin-intralipid exhibited best activity against Mucorales, followed by posaconazole, while limited efficacy was seen for liposomal amphotericin B and isavuconazole. Pharmacokinetic properties of the tested antifungals within this alternative host system partly explain the limited treatment efficacy. In conclusion, G. mellonella represents a useful invertebrate infection model for studying virulence of mucormycetes, while evaluation of treatment response was limited.


Assuntos
Antifúngicos/uso terapêutico , Modelos Animais de Doenças , Larva/microbiologia , Lepidópteros/microbiologia , Mucorales/efeitos dos fármacos , Mucorales/patogenicidade , Mucormicose/tratamento farmacológico , Anfotericina B/farmacocinética , Anfotericina B/uso terapêutico , Animais , Antifúngicos/farmacocinética , Farmacorresistência Fúngica , Testes de Sensibilidade Microbiana , Mucor/efeitos dos fármacos , Mucor/patogenicidade , Mucormicose/microbiologia , Nitrilas/farmacocinética , Nitrilas/uso terapêutico , Piridinas/farmacocinética , Piridinas/uso terapêutico , Rhizopus/efeitos dos fármacos , Rhizopus/patogenicidade , Triazóis/farmacocinética , Triazóis/uso terapêutico , Virulência
3.
Z Naturforsch C J Biosci ; 71(1-2): 15-9, 2016.
Artigo em Inglês | MEDLINE | ID: mdl-26812868

RESUMO

The new cyclic heptapeptide unguisin F (1) and the known congener unguisin E (2), were obtained from the endophytic fungus Mucor irregularis, isolated from the medicinal plant Moringa stenopetala, collected in Cameroon. The structure of the new compound was unambiguously determined on the basis of one- and two-dimensional NMR spectroscopy as well as by high-resolution mass spectrometry. The absolute configuration of the amino acid residues of 1 and 2 was determined using Marfey's analysis. Compounds 1 and 2 were evaluated for their antibacterial and antifungal potential, but failed to display significant activities.


Assuntos
Mucor/química , Mucormicose/tratamento farmacológico , Peptídeos Cíclicos/química , Antibacterianos/química , Antibacterianos/isolamento & purificação , Antifúngicos/química , Antifúngicos/isolamento & purificação , Bactérias/efeitos dos fármacos , Bactérias/patogenicidade , Fungos/efeitos dos fármacos , Fungos/patogenicidade , Humanos , Espectroscopia de Ressonância Magnética , Estrutura Molecular , Mucor/patogenicidade , Mucormicose/microbiologia , Mucormicose/patologia , Peptídeos Cíclicos/isolamento & purificação , Peptídeos Cíclicos/farmacologia
4.
Semin Respir Crit Care Med ; 32(6): 693-702, 2011 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-22167397

RESUMO

Mucormycosis (formerly zygomycosis) is a life-threatening opportunistic mycosis that infects a broad range of hosts with qualitative or quantitative defects in innate immunity, including patients with severe neutropenia, recipients of corticosteroids or other immunosuppressive medications, poorly controlled diabetes mellitus, and those with iron overload states. Mucormycosis has recently emerged as breakthrough sinopulmonary infection in hematologic patients and recipients of transplantation being on antifungal prophylaxis with Aspergillus-active antifungals that lack activity against Mucorales. Unlike pulmonary aspergillosis, the prognosis and outcome of pulmonary mucormycosis have not improved significantly over the last decade, mainly because of difficulties in early diagnosis and the limited activity of current antifungal agents against Mucorales. Recent evidence suggests a critical role for iron metabolism and fungal-endothelial cell interactions in pathogenesis of mucormycosis, and holds promise for development of novel therapeutic strategies. Currently, prompt initiation of antifungal therapy with a lipid amphotericin B-based regimen, reversal of underlying host factors, and aggressive surgical approach offers the best chances for survival of patients infected with this devastating mycosis.


Assuntos
Hospedeiro Imunocomprometido , Pneumopatias Fúngicas , Mucormicose , Infecções Oportunistas , Antifúngicos/uso terapêutico , Desbridamento , Humanos , Oxigenoterapia Hiperbárica , Pneumopatias Fúngicas/diagnóstico , Pneumopatias Fúngicas/epidemiologia , Pneumopatias Fúngicas/imunologia , Pneumopatias Fúngicas/fisiopatologia , Pneumopatias Fúngicas/terapia , Mucor/imunologia , Mucor/patogenicidade , Mucorales/imunologia , Mucorales/patogenicidade , Mucormicose/diagnóstico , Mucormicose/epidemiologia , Mucormicose/imunologia , Mucormicose/fisiopatologia , Mucormicose/terapia , Infecções Oportunistas/complicações , Rhizomucor/imunologia , Rhizomucor/patogenicidade , Rhizopus/imunologia , Rhizopus/patogenicidade
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA